A subscription to JoVE is required to view this content. Sign in or start your free trial.
Presented here is a protocol using Leishmania major promastigotes to determine the binding, cytotoxicity, and signaling induced by pore-forming toxins. A proof-of-concept with streptolysin O is provided. Other toxins can also be used to leverage the genetic mutants available in L. major to define new mechanisms of toxin resistance.
Understanding the function and mechanism of pore-forming toxins (PFTs) is challenging because cells resist the membrane damage caused by PFTs. While biophysical approaches help understand pore formation, they often rely on reductionist approaches lacking the full complement of membrane lipids and proteins. Cultured human cells provide an alternative system, but their complexity and redundancies in repair mechanisms make identifying specific mechanisms difficult. In contrast, the human protozoan pathogen responsible for cutaneous leishmaniasis, Leishmania major, offers an optimal balance between complexity and physiologic relevance. L. major is genetically tractable and can be cultured to high density in vitro, and any impact of perturbations on infection can be measured in established murine models. In addition, L. major synthesizes lipids distinct from their mammalian counterparts, which could alter membrane dynamics. These alterations in membrane dynamics can be probed with PFTs from the best-characterized toxin family, cholesterol-dependent cytolysins (CDCs). CDCs bind to ergosterol in the Leishmania membrane and can kill L. major promastigotes, indicating that L. major is a suitable model system for determining the cellular and molecular mechanisms of PFT function. This work describes methods for testing PFT function in L. major promastigotes, including parasite culture, genetic tools for assessing lipid susceptibility, membrane binding assays, and cell death assays. These assays will enable the rapid use of L. major as a powerful model system for understanding PFT function across a range of evolutionarily diverse organisms and commonalities in lipid organization.
Pore-forming toxins (PFTs) are the largest family of bacterial toxins1, but the mechanisms by which they perforate and destroy cells are poorly understood. The best-studied family of pore-forming toxins is that of cholesterol-dependent cytolysins (CDCs). CDCs are primarily synthesized by gram-positive bacteria, including the causative agent of necrotizing fasciitis, Streptococcus pyogenes2. S. pyogenes secretes the CDC streptolysin O (SLO), which binds to sterols in the plasma membrane of host cells as monomers, oligomerizes, and inserts ~20-30 nm pores into the membrane1. The role that lipids play in this process remains poorly determined.
One approach to studying lipid-CDC interactions is the use of chemically defined liposomes. While defined liposomes provide information on the necessary thresholds of lipids to sustain toxin binding and pore formation3,4, they do not fully recapitulate cellular functions. For example, reconstituted liposomes lack the lipid asymmetry of mammalian hosts and lipid modifications in response to toxins5. One alternative to liposomes is to use mammalian cell lines. While these cell lines are more physiologically relevant, there is a large degree of redundancy in toxin sensing and resistance mechanisms2. As a consequence, the repair pathways used to resist CDCs remain poorly determined. Notably, Ca2+ influx is the primary activator of membrane repair1. Downstream of Ca2+ influx, multiple pathways are engaged, including a ceramide-dependent repair6,7 and a MEK-dependent repair pathway6. These pathways interact with other protein effectors, including the endosomal sorting complex required for transport (ESCRT)8, and annexins6,9,10. Dissecting these pathways in mammalian cells is challenging due to the redundancy, which muddles data interpretation.
One way to balance complexity with simplicity for dissecting repair pathways is the use of simpler organisms, such as protozoan pathogens in the genus Leishmania. Leishmania sp. cause leishmaniasis in humans and other animals. Leishmaniasis ranges from cutaneous leishmaniasis (self-limited skin lesions) to the fatal visceral leishmaniasis (hepatosplenomegaly), depending on the species and other factors11. Leishmania major, the causative agent of cutaneous leishmaniasis, is transmitted to humans via a sandfly vector and is used to understand Leishmania function and infection12. In addition, Leishmania sp. are digenic12. They exist as intracellular mammalian macrophage parasites termed amastigotes and as free-swimming, flagellated promastigotes in the sandfly12. L. major promastigotes can be cultured in serum-supplemented media such as M199 to high density13. Promastigotes are also genetically tractable; many gene knockouts exist, including those targeting lipid biosynthesis pathways13. These knockouts can be evaluated for growth and differences in infectivity and lesion development via infection of Balb/c mice13.
In addition to the relative ease of Leishmania culture and the range of lipid biosynthesis knockouts, the parasite has a simpler genome than mammals. The best-characterized species of Leishmania is L. major, which has many existing genetic tools, such as mutants with defective lipid metabolism14. Notably, many repair proteins are absent. L. major has no homologs identified to date for key mammalian repair proteins such as annexins. This enables the characterization of evolutionarily conserved repair pathways without the complexity of mammalian systems. However, repair pathways have not been characterized in Leishmania to date. At the same time, key signaling pathways involved in repair, such as the MEK pathway6, are conserved in Leishmania sp.15,16, though homologs need to be validated. The mitogen-activated protein kinase (MAPK) pathway is well-studied in L. mexicana, where it contributes to intracellular survival and thermostability in mammalian cells and controls metacyclogenesis16. In Leishmania sp., 10 of the 15 MAPKs have been characterized17. LmMAPK9 and LmMAPK13 are predicted to be the most similar to mammalian ERK1/2 based on identity in the conserved phosphorylation lip sequence. The phosphorylation lip sequence is TEY for both mammalian ERK1/2 and LmMAPK9 and LmMAPK13. However, eight of the Leishmania MAPKs have a TDY phosphorylation motif15. At least two homologs of MEK have been identified in Leishmania sp., LmxMKK18 and MEKK-related kinase (MRK1)19. This suggests that insights identified in Leishmania could translate to mammalian systems. Where they do not translate to mammalian systems, they represent therapeutic targets for treating leishmaniasis.
In order to use L. major promastigotes to study membrane repair and interactions with toxins, medium-throughput techniques are needed. While high-resolution live cell imaging enables the visualization of labeled proteins and membranes in real time, it is low throughput and may not measure cellular survival. Medium-throughput viability assays include dye uptake measured by flow cytometry, the measurement of mitochondrial activity, or the release of cellular proteins like lactate dehydrogenase (LDH). In mammalian cells, LDH assays do not quantitatively measure cell death20. Furthermore, population-based assays like LDH release or mitochondrial activity do not allow robust single-cell or multiparametric analysis20. In contrast, flow cytometry-based assays enable multiparametric single-cell analysis20. However, these assays have not been applied to understanding toxin biology or responses to toxins in L. major promastigotes.
In this study, SLO is used as a tool to understand the plasma membrane perturbation of the sphingolipid null mutant of L. major in two different buffers-the M199 media routinely used to culture L. major promastigotes and the simpler Tyrode's buffer. A medium-throughput flow cytometry assay is described and used to generate toxin dose-response curves. Data from the flow cytometric assay are modeled to a logistic curve to determine the LC50 values. With this information, a sublytic dose of SLO can be determined so that MAPK antibodies can be validated using western blotting.
All appropriate guidelines and standard microbiological, safety, and cell culture practices were employed for the use and handling of the RG2 pathogen Leishmania major and recombinant DNA. All experiments with live L. major were performed in a biosafety cabinet in a BSL-2 certified laboratory. The work was overseen by the Texas Tech University Institutional Biosafety Committee.
NOTE: From a safety perspective, live L. major promastigotes are Risk Group 2 pathogens. Handle using appropriate containment, precautions, and oversight from the Institutional Biosafety Committee (IBC). Handle toxic substances and chemicals in accordance with institutional procedures for toxic substances. If recombinant toxins are used, IBC approval and oversight may be needed for recombinant DNA work.
1. Cultivation and preparation of L. major promastigotes
2. Cytotoxicity assay
3. Protein analysis of toxin-challenged L. major promastigotes
Increased promastigote sensitivity to SLO in Tyrode's buffer compared to M199
The SLO sensitivity of L. major promastigotes was compared between different assay buffers. Wild-type, spt2-, and spt2-/+SPT2 promastigotes were challenged with SLO in serum-free M199 or Tyrode's buffer supplemented with 2 mM CaCl2 for 30 min prior to analysis on a flow cytometer. Suitable parasites for analysis were single cells identified by forwar...
In this study, methods to study the molecular mechanisms and functions of PFTs were described, using the human pathogen Leishmania major as a model system. A medium-throughput flow cytometry-based cytotoxicity assay to measure single-cell viability was developed. Viability is quantitative at the population level because LC50 values can be calculated from the dose-response curve using logistic modeling. As a proof-of-principle, a flow cytometric assay was used to illustrate that the choice of media can...
This work was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health grant R21AI156225 to PAK and KZ (co-I) and R01AI139198 to KZ (co-I). CH would like to acknowledge the Department of Biological Sciences for the Teaching Assistantship provided during the time of this study.
The funding agencies had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; nor in the decision to publish the results. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. The authors declare they have no competing conflicts of interest.
The authors would like to thank members of the Keyel and Zhang labs for their critical review of the manuscript. The authors thank the College of Arts and Sciences Microscopy for the use of facilities.
Name | Company | Catalog Number | Comments |
1.2 mL microtiter (Marsh) tubes | Fisher | 02-681-376 | Cytotoxicity assay |
1.5 mL microcentrifuge tube | Fisher | 05-408-129 | Toxin dilutions |
15 mL centrifuge tube | Avantor VWR (Radnor, PA) | 89039-666 | To hold cells and media |
1x Phosphate buffered saline (PBS) | Fisher | BP399 | For cell processing |
3% H2O2 | Walmart (Fayetteville, AR) | N/A | For ECL |
5x M199 | Cell-gro | 11150067 | Basal growth media for L. major promastigotes |
Biosafety cabinet | Baker | To culture cells in sterile conditions | |
Bovine serum albumin (BSA) | Fisher | BP1605-100 | Fraction V acceptable purity |
CaCl2 | Fisher | BP510-100 | Stock concentration 100 mM |
Centrifuge | Thermo Fisher | Heraeus Megafuge 40R | To pellet the cells from culture |
Cy5 Mono-reactive dye pack | Cytiva (Marlborough, MA) | PA25031 | Fluorophore label for toxins |
Digital dry bath | Benchmark | BSH1002 | To denature protein samples |
EGTA | Amresco | 0732-100G | Stock concentration 0.5 M |
Excel | Microsoft (Redmond, VA) | Data analysis software | |
Flow cytometer (4-laser Attune NxT) | Fisher | Cytometer for data acquisition | |
FlowJo | BD (Ashland, OR) | Software | |
Formaldehyde | Fisher | BP531-500 | Fixative for counting cells |
G418 | Fisher | BP673-1 | Selection agent for cells |
Hellmanex III | Sigma | Z805939 | Dilute 1:4 for cleaning cytometer |
Hemacytometer | Fisher | 0267151B | For counting cells |
Human red blood cells | Zen-bio (Durham, NC) | SER-10MLRBC | To validate toxin activity |
Ice bucket | |||
Light microscope | Nikon | Eclipse 55i | To visualize cells |
Nitrocellulose | Fisher | 88018 | For probing proteins via antibodies |
Pipettors and tips | Avantor VWR | To dispense reagents | |
Power supply | Bio-Rad | To run SDS-PAGE and transfers | |
Propidium iodide | Biotium | 40016 | Stock concentration 2 mg/mL in water |
Protein ladder | Bio-Rad | 161-0373 | To determine molecular weight of proteins |
SDS-PAGE Running Apparatus (Mini Protean III) | Bio-Rad | 165-3302 | To separate proteins based on their size |
Sealing tape | R&D | DY992 | To seal plates with cells |
Streptolysin O C530A plasmid insert | Cloned into pBAD-gIII vector (Reference: 7) | ||
Streptolysin O C530A toxin | Lab purified | Specific activity 4.34 x 105 HU/mg | |
Swinging bucket rotor | Thermo Fisher | 75003607 | To centrifuge cells |
V-bottom plate | Greiner Bio-one | 651206 | For cytotoxicity assay |
Vortex | Benchmark | BV1000 | To mix cells |
Western blot imaging system (Chemi-doc) | Bio-Rad | To visualize proteins by western blot | |
Western Blot Transfer Apparatus (Mini Protean III) | Bio-Rad | 170-3930 | Transfer proteins to nitrocellulose |
Whatman Filter paper | GE Healthcare Life Sciences | 3030-700 | Used in transfer of proteins to nitrocellulose |
Antibody | |||
Anti-ERK antibody | Cell Signaling Technologies | Cat# 9102S | Rabbit (1:1000 dilution) |
Anti-lipophosphoglycan (LPG) antibody | CreativeBioLabs | Cat# WIC79.3 | Mouse (1: 1000) |
Anti-MEK antibody | Cell Signaling Technologies | Cat# 9122L | Rabbit (1:1000) |
Anti-mouse IgG, HRP conjugate | Jackson Immunoresearch | Cat#715-035-151 | Donkey (1:10000) |
Anti-phosphoERK antibody | Cell Signaling Technologies | Cat# 9101S | Rabbit (1:1000) |
Anti-pMEK antibody | Cell Signaling Technologies | Cat# 9121S | Rabbit (1:1000) |
Anti-rabbit IgG, HRP conjugate | Jackson Immunoresearch | Cat#711-035-152 | Donkey (1:10000) |
Anti-tubulin antibody | Sigma | Cat# T5168 | Mouse (1: 2000) |
Leishmania major Genotypes | Reference: 13 | ||
Episomal addback (spt2-/+SPT2) | Δspt2::HYG/Δspt2:PAC/+pXG-SPT2 | ||
Serine palmitoyltransferase subunit 2 knockout (spt2-) | Δspt2::HYG/Δspt2::PAC | ||
Wild type (WT) | LV39 clone 5 (Rho/SU/59/P) |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved